Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping

Matthew G. Dimond, BS,a Nasrien E. Ibrahim, MD,a Mona Fiuzat, PharmD,b John J.V. McMurray, MD,c JoAnn Lindenfeld, MD,d Tariq Ahmad, MD, MPH,e Biykem Bozkurt, MD, PhD,f Michael R. Bristow, MD, PhD,g Javed Butler, MD, MPH, MBA,h Peter E. Carson, MD,i G. Michael Felker, MD, MHS,b Mariell Jessup, MD,j Jaime Murillo, MD,k Toru Kondo, MD, PhD,c,l Scott D. Solomon, MD,m William T. Abraham, MD,n Christopher M. O’Connor, MD, a,b Mitchell A. Psotka, MD, PhDa

HIGHLIGHTS
• Heart failure is a complex syndrome categorized by LVEF.
• Although flawed, LVEF is prognostic for adverse events and predicts response to some medical therapies.
• Simplified LVEF terminology may improve utilization of heart failure medical therapy.
• Novel therapies should be characterized across the entire LVEF spectrum to best determine their utility.

ABSTRACT
Heart failure (HF) is a complex syndrome traditionally classified by left ventricular ejection fraction (LVEF) cutpoints. Although LVEF is prognostic for risk of events and predictive of response to some HF therapies, LVEF is a continuous variable and cutpoints are arbitrary, often based on historical clinical trial enrichment decisions rather than physiology. Holistic evaluation of the treatment effects for therapies throughout the LVEF range suggests the standard categorization paradigm for HF merits modification. The multidisciplinary Heart Failure Collaboratory reviewed data from large-scale HF clinical trials and found that many HF therapies have demonstrated therapeutic benefit across a large range of LVEF, but specific treatment effects vary across that range. Therefore, HF should practically be classified by association with an LVEF that is reduced or not reduced, while acknowledging uncertainty around the precise LVEF cutpoint, and future research should evaluate new therapies across the continuum of LVEF. (J Am Coll Cardiol Case Rep 2024;12:451–460) Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
left ventricular ejection fraction (LVEF) measurement remains a staple of heart failure (HF) research, classification, and clinical management. The recently updated Canadian, European, and United States HF guidelines elaborate the growing evidence for the treatment of patients with HF without a reduced LVEF distinctly from those with a reduced LVEF. The guidelines organize HF into categories based on LVEF, including heart failure with reduced ejection fraction (HFrEF) with LVEF ≤40%, heart failure with preserved ejection fraction (HFpEF) with LVEF ≥50%, heart failure with mildly reduced (formerly, mid-range) ejection fraction (HFmrEF) with LVEF 41% to 49%, and heart failure with improved ejection fraction (HFimpEF) with LVEF >40% but previous LVEF ≤40% (Figure 1).

LVEF is useful in clinical care and for research because it is broadly prognostic of adverse events in patients with HF and can predict response to many HF medical therapies. As foundational inclusion criteria for multiple practice-changing clinical trials, traditional LVEF cutoffs are tied to lifesaving clinical advances and are straightforward to apply in routine clinical practice. However, LVEF is a continuous rather than a dichotomous variable and only one of many biomarkers that may help phenotype patients with HF to improve their clinical care.

In addition, although the guidelines currently describe the category of HF without a reduced LVEF as “preserved,” or HFpEF, this terminology intimates that myocardial structure and function are not altered. In contrast, a “normal” LVEF does not imply normal myocardial function and substantial evidence demonstrates that patients with HF but without a reduced LVEF have decreased myocardial strain, elevated ventricular filling pressures, and increased risk of adverse outcomes.

The Heart Failure Collaboratory is a multi-stakeholder consortium composed of clinical investigators, physicians, payers, patients, and representatives from industry, the Food and Drug Administration, and other government agencies. The HF-ARC (Heart Failure Collaboratory convened the Heart Failure-Academic Research Consortium) forum to review data from multiple landmark clinical trials, discuss potential limitations of the current classification of HF based on LVEF, and provide consensus recommendations. Although prior publications have commented on the utility or disutility of LVEF, this expert panel consensus updates the discussion with the most recent sodium glucose co-transporter 2 inhibitor (SGLT2i) clinical trial data, and provides novel concise recommendations for clinical and research use of LVEF in the context of the latest HF guidelines.

Until more precise and nuanced biomarkers are available for HF classification, we argue that pragmatically, LVEF remains flawed but useful for HF clinical management and research. Clinically, HF should be divided into 2 broad categories based on LVEF: heart failure with reduced ejection fraction (HFrEF) and HF without a reduced LVEF (Figure 1). We acknowledge that there is a region of overlap between these syndrome populations, and thus uncertainty of assignment for patients with LVEF measurements that lie within generally accepted normal population values. “HF without a reduced LVEF” appropriately acknowledges the heterogeneity of disease processes that cause the HF syndrome in this population, and omitting a precise cutoff between the groups recognizes the evidentiary uncertainty around that breakpoint due to measurement and physiologic variability. Nevertheless, although these 2 LVEF groups generally signal the therapeutic benefits clinicians can reasonably expect patients to experience, novel therapies should continue to be investigated for utility across the entire continuum of LVEF to facilitate evidence generation among all patients with HF.

LVEF: IMPERFECT BUT USEFUL

LVEF is imperfect because it can vary by imaging modality, hemodynamic loading conditions, heart rhythm, and on repeat measures even by the same modality for a single individual. On a population level, LVEF assessment also varies by age, race, and sex, as women have a slightly higher normal range. Despite these limitations, decades of clinical trial evidence support classification of HF by LVEF, and LVEF will remain useful until HF can be better phenotyped using proteomics, genomics, other imaging modalities such as strain echocardiography, or perhaps additional biomarkers currently under investigation. Although the strengths of LVEF are discussed in the following, improved phenotyping of and individualized treatment for patients with HF remains critically important as an essential mechanism to advance clinical care.

LVEF is valuable in HF because it possesses both prognostic utility (identifies patients likely to have a disease-related event) and predictive capabilities (identifies patients likely to respond to an intervention). Patients with lower LVEF are at greater risk of adverse events, including higher absolute rates of
cardiovascular mortality, hospitalization, and sudden cardiac death. This was among the reasons that clinical trials initially, and now pervasively, used LVEF as an enrollment and enrichment criterion: lower LVEF meant higher event rates, greater statistical power, and better opportunity to demonstrate a treatment benefit for a novel therapeutic. Although clinical trials have used varied LVEF cutpoints for enrollment (Figure 2), the impact of these historical decisions was to limit evidence generation to patients only with LVEF in these ranges.

LVEF predicts both the expected treatment effect and magnitude across its continuum, but only for some therapies, and not as a dichotomous instrument. For neurohormonal antagonists of the renin-angiotensin-aldosterone system, LVEF captures the likelihood of therapeutic effect as a response variable until LVEF passes above values generally regarded as the lower limit of normal, in the range of 50% to 55%.8,9 Nonetheless, their effectiveness is variable for patients with higher values of LVEF, as some are effective into the LVEF range above 55% and many are not (Central Illustration, Table 1).

**SPECIFIC HF THERAPEUTICS ACROSS THE RANGE OF LVEF**

Multiple medications used for the treatment of HFrEF have been studied for effectiveness across the range of LVEF. In post hoc analysis of the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program, candesartan benefited patients across the continuous range of LVEF up to above 60%.21 However, because the overall incidence of cardiovascular morbidity and mortality declined for patients with LVEF closer to or in the normal range, the treatment benefit on morbidity and mortality also declined in those patients. In addition, the relative benefit of candesartan varied by outcome over the range of LVEF: the benefit on mortality was principally seen at lower LVEF values, whereas the benefit on hospitalization extended into the normal range of LVEF.

The TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial enrolled patients with LVEF ≥45%. Although the trial did not meet its primary endpoint, post hoc analyses suggested greater therapeutic benefit for spironolactone at the lower end of the included LVEF spectrum, and a reduction in the primary endpoint of cardiovascular death, HF hospitalization, or aborted cardiac arrest and HF hospitalization was observed up to an LVEF of 50%.22 A combined analysis of trials with spironolactone and eplerenone suggested that, similar to candesartan, the overall therapeutic benefit with mineralocorticoid receptor antagonists extends into the normal range of LVEF, again with the effect on cardiovascular...
mortality more apparent at lower LVEF, and the effect on hospitalization extending farther into the normal LVEF range.23

A meta-analysis of 11 beta-adrenergic receptor antagonist trials showed that, although the treatment effect was most pronounced in patients with LVEF <40%, beta-blockers reduced morbidity and mortality for patients with LVEF <50%, but with diminished evidence for a treatment effect at higher LVEF.24

Evidence for the treatment benefit of the cardiac glycoside digoxin is greatest at the lower end of the LVEF spectrum, below LVEF of 45%. The ancillary arm of the DIG (Digitalis Investigation Group) trial enrolled patients with LVEF >45% but the relative risk reduction in cardiovascular death and HF hospitalization was smaller in magnitude and did not meet statistical significance.19 The cardiac myosin activator omecamtiv mecarbil was only studied in patients with an LVEF ≤35%. Although the overall study demonstrated a modest treatment benefit, a larger treatment effect was found for patients with LVEF <28% in post hoc analyses, and it may have greatest potential utility in only this lower range of LVEF.25,26

Post hoc analyses of sacubitril/valsartan trials also showed effectiveness across the range of HFpEF and for patients above LVEF 50% to 55%. A prespecified pooled analysis from the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity, 2014) demonstrated a beneficial treatment effect for the composite of total HF hospitalization or cardiovascular death for sacubitril/valsartan up to an LVEF of 55%.27 Similar to other neurohormonal agents, the effect on mortality was less prevalent at higher LVEF than the effect on morbidity. Along with other neurohormonal
antagonists, the relative and absolute risk reduction with treatment diminishes at the higher range of LVEF, particularly above LVEF 50% to 55%.

SGLT2i also demonstrated therapeutic benefit across the spectrum of LVEF. Empagliflozin reduced hospitalizations across the range of LVEF extending up to 65% in a pooled analysis of nearly 10,000 patients from the EMPEROR-Reduced and EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure) programs, but there was no evidence of benefit above LVEF of 65%. A prespecified pooled analysis of individual patient data from more than 11,000 patients from 2 clinical trials, DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Live of Patients With Preserved Ejection Fraction Heart Failure), revealed a similar treatment benefit across the range of LVEF, with no evidence of treatment effect modification based on LVEF. Dapagliflozin thus stands in contrast to the neurohormonal antagonists with apparent effectiveness that reliably extends into and above the normal range of LVEF.

These data support that for currently available HF medical therapies in clinical practice, LVEF can be practically dichotomized into reduced and nonreduced. In patients with the HF syndrome and LVEF below the normal range expected for their demographics, treatment with neurohormonal antagonists and SGLT2i can be anticipated to reduce risk of morbidity and mortality. For patients with LVEF closer to the lower limits of normal, the relative and absolute treatment benefits attenuate, as the overall risk of death and hospitalization and the magnitude of benefit are proportional to the decrement in LVEF. For neurohormonal antagonists in patients with normal or supranormal LVEF, the expected treatment responses are distinct, with little effect on mortality and diminishing effects on morbidity, except for SGLT2i.

In contrast, the clinical use of the more recently and arbitrarily defined category HFmrEF is not supported by independent clinical trial data, and the utility of therapies in this range can only be extrapolated from their adjacent trends. Specifically, the HRs for benefit with 95% CIs for beta-blockers, spironolactone, and sacubitril/valsartan in the LVEF range of 40%-49% span 0.60-1.13, 0.50-1.05, and 0.73-1.10, respectively (Table 1). It is only when the context of the rest of the LVEF spectrum is accounted for that their utility in the HFmrEF range can be surmised. The lack of utility of HFmrEF may be because LVEF measurements are dynamic and demonstrate operator-dependent variability on repeat assessment and are thus impractical over the narrow LVEF range of HFmrEF. In addition, data supportive of HFmrEF as a phenotype come only from post hoc analyses of large trials and observational analyses from registries, but no clinical trials have tested interventions separately in this population. Finally, use of HFmrEF as a clinical concept does not augment implementation of effective HF medications except when lumped together with HFrEF and may confuse clinicians otherwise seeking to use more HF medical therapy. Therefore, we advise the elimination of HFmrEF as a phenotypic category because of its impracticality, lack of evidence of utility, and potential for harm.

HFimpEF is another subcategory of HFrEF that for clinical simplicity should be included and treated under the HFrEF rubric. The TRED-HF (Therapy withdrawal in REcovered Dilated cardiomyopathy trial) demonstrated that patients with prior HFrEF that had improvement with appropriate HF medical therapy would frequently relapse with removal of that medical therapy. In addition, molecular and biomarker testing of hearts with improved LVEF treated with medical, electrophysiologic device, or mechanical circulatory support device therapies demonstrate persistent myocardial abnormalities that support the concept of myocardial remission rather than recovery in response to these therapies. Therefore, as patients with HFimpEF have HFrEF on a molecular level and remain at elevated risk of adverse events if taken off therapy, HFimpEF should be conceptualized and treated as HFrEF.

Future trials should enroll patients across a wide range of LVEF. In this way, the benefits of SGLT2i are a guide for the future: if SGLT2i had not been studied across the full range of LVEF, numerous patients would not currently be able to reap their rewards. Novel HF therapies should be evaluated across the continuum of LVEF because treatment benefits are unlikely to stop at artificial borders imposed by traditional LVEF cutoffs while the pathophysiologic targets for therapies likely span the range of LVEF.

**HF Devices Across the Range of LVEF**

Evidence from HF device development reinforce the LVEF lessons learned from drug development. HF devices demonstrate conceptually similar differences in effectiveness across the range of LVEF, and some have been developed for use only in specific subranges of LVEF, while others for all patients with HF. Guidelines recommend implantable cardioverter-defibrillators in symptomatic patients at highest risk, typically those with LVEF ≤35%, or in those with...
CENTRAL ILLUSTRATION  Treatment Effect of Medications for Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction

A  ARB  CV Death or HF Hospitalization

B  ARNI  CV Death or HF Hospitalization

C  SGLT2i  CV Death or HF Hospitalization

D  MRA  CV Death or HF Hospitalization

E  Digitalis  CV Death or HF Hospitalization


Continued on the next page
LVEF $\leq 30\%$ and a recent myocardial infarction. The evidence for benefit from cardiac resynchronization therapy (CRT) is primarily for high-risk patients with LVEF $\leq 35\%$ and a wide left bundle branch block pattern. However, similar to the growing appreciation of neurohormonal antagonism benefit at higher LVEF, the BLOCK-HF (Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atriorectic Block) trial suggests a treatment effect for CRT in patients with LVEF 35 to 50%; however, the MIRACLE EF study (NCT01735916) of CRT with higher LVEF was unable to recruit.32,33 Uniquely, cardiac contractility modulation is only approved for patients with LVEF between 25% and 45% who are not candidates for CRT, although investigation of cardiac contractility modulation therapy for patients with LVEF of 40% to 60% is ongoing.34 In contrast, utilization of the CardioMEMS device (Abbott Cardiovascular) reduces HF hospitalization regardless of LVEF.

THE FUTURE OF LVEF AND NOVEL HF PHENOTYPING

Because of the described variable effectiveness of some therapies across LVEF at baseline in HF clinical trials and to identify LVEF as a defining predictor of interest, including in prespecified subgroups. Furthermore, the trajectory of LVEF over time as a response to a new treatment could provide additional insight into the effect on cardiac remodeling. Although LVEF is a crude biomarker, the relationship between the degree of pathologic eccentric molecular and structural remodeling and drug response should remain a research focus for all novel therapies, because it may facilitate discovery of better phenotyping characteristics. Currently available HF data do not rule out qualitative molecular differences within the spectrum of LVEF that could dictate differential responses in some ranges to some therapies. Ongoing diligence may help meet the critical need for novel biomarkers that better phenotype patients into prognostic and predictive groups. Perhaps the implementation of "umbrella" trials to test multiple interventions across a broad spectrum of patients, and to sub-phenotype them using non-LVEF biomarkers, would allow collection of sufficient data to conclusively characterize expected treatment benefits of particular therapies throughout the continuum of HF.

Nevertheless, improved phenotyping methodologies are likely to be complex and unlikely to replace LVEF in the near future. It is improbable that any single undescribed biomarker will identify treatment responders across all classes of HF therapies, and more plausible that biomarkers will vary by treatment modality. Useful phenotypic characteristics may include both pathophysiologic biomarkers such as aldosterone levels, and indicators of disease severity such as ST2 gene expression, or N-terminal pro-B-type natriuretic peptide levels for both. Furthermore, pathophysiologic biomarkers for newly developed therapies such as SGLT2i may yet be unknown.

Cardiac amyloidosis will hopefully serve as a roadmap for how improved HF phenotyping can lead to the identification of pathophysiologically distinct disease processes currently housed under HF that may be effectively treated with targeted molecular therapies. Individuals with cardiac amyloidosis most commonly present with the HF syndrome but without a reduced LVEF and are frequently undiagnosed. It is presumed that substantial proportions of patients enrolled in HFpEF clinical trials have likely had cardiac amyloidosis and their inclusion may have altered trial results because these patients often do not tolerate HF medications.37 Yet patients with...
amyloidosis respond to directly targeted disease-modifying therapies that have no effect on other patients with HF. Technetium pyrophosphate scintigraphy, genetic testing, and molecular diagnostics have facilitated noninvasive diagnosis and treatment, and effectively transformed care for patients with cardiac amyloidosis and lifted it from under the mantle of HF.

CONCLUSIONS

The wealth of data that support differential HF treatment effects by LVEF, or the lack thereof for some therapies, argue for the following proposed changes in the conceptualization and use of LVEF as a biomarker and updated guidelines for the classification and management of HF based on LVEF. Simplified and practical terminology to group patients by LVEF will hopefully facilitate improved utilization of HF medical therapy, known colloquially as guideline-directed medical therapy, by all clinicians and thereby improve care and outcomes for patients with HF. If the LVEF is below the generally accepted normal range of 50% to 55%, treat with therapies for HFrEF (Figure 1, Central Illustration). In contrast, if the LVEF is not reduced, then more individualized and personalized diagnostic and treatment paradigms are needed, including shared decision-making, and often specialty referral. HFrEF should be eliminated from the guidelines and clinical practice, and HFmrEF should be classified and treated as a subtype of HFrEF. Although medications conventionally indicated for HF with a reduced LVEF such as spironolactone and sacubitril/valsartan should be considered to prevent hospitalizations for patients in the border zone around normal LVEF, such a regimen should not be considered sufficient and additional treatment modalities should be developed in addition or as alternatives because the likelihood and magnitude of response in this region are diminished. In contrast, ongoing characterization of the effectiveness of novel therapies across the entire spectrum of LVEF and improved phenotyping with development of additional targeted therapeutics for patients with HF without a reduced LVEF remain the challenging research target.

ACKNOWLEDGMENTS The authors thank Drs Norman Stockbridge and Bram Zuckerman from the U.S. Food and Drug Administration for their support of the Heart Failure Collaboratory.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

Dr Ibrahim has received consulting fees from Cytokinetix. Dr McMurry discloses payments to his employer, Glasgow University, for his work on clinical trials, consulting, and other activities: Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardurion, Cytokinetix, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; and personal payments: Abbott, Alkem Metabolics, Eris Lifesciences, Hickma, Ionis, Lupin, ProAdvise Communications, Sun Pharmaceuticals, and Servier. Dr Lindenfeld has received consulting fees from Abbott, Alleviant, Boston Scientific, Cordio, CRVx, Edwards Lifesciences, Medtronic, Merck, Whiteswell, Vascular Dynamics, and V-Wave. Dr Bozkurt has received consulting fees from AstraZeneca, Bristol Myers Squibb, GenoPharmaceuticals, Baxter, Sanofi, Relypsa, Vifor, Roche, and Boehringer Ingelheim; has served on the steering committee of Relypsa and Renovacor; has served on a Clinical Event Committee for Abbott Pharmaceuticals; and has served on the Data Safety Monitoring Board for LivaNova Pharmaceuticals. Dr Bristow has served as a director, officer, partner, advisor, consultant, or trustee for ARCA biopharma; has received research grants from the American Heart Association and National Institute of Allergy and Infectious Diseases; and has received personal payments from ARCA biopharma. Dr Butler has received consulting fees from Boehringer Ingelheim, Cardior, CVRx, Foundry, G3 Pharma, Imbia, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, Sanofi, Sequana Medical, V-Wave Ltd, and Vifor; and is a Trial Executive Committee member of the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance (trial sponsor). Dr Carson has received consulting fees from Boehringer Ingelheim and IQVIA related to work on Clinical Events Committees. Dr Felker has received research grants from the National Heart, Lung, and Blood Institute, American Heart Association, Amgen, Bayer, BMS, Novartis, Daxor, Merck, Cytokinetix, and CSL-Behring; has acted as a consultant to Novartis, Amgen, BMS, Cytokinetix, Innolife, Medtronic, Cardionomic, Boehringer Ingelheim, American Regent, Abbott, AstraZeneca, Regeneron, Regenere, Myovant, Sequana, Windtree Therapeutics, Rocket Pharma, and Whiteswell; and has served on clinical endpoint committees/data safety monitoring.
boards for Amgen, Merck, Medtronic, EBR Systems, V-Wave, and LivaNova. Dr Murillo is an employee and stockholder of UnitedHealth Group. Dr Kondo has received grants from the Uehara Memorial Foundation and the Japanese Heart Failure Society Tsuchiya Foundation for research activity at the University of Glasgow; and has received lecture fees from Ono Pharmaceutical Co, Ltd, Otsuka Pharmaceutical Co, Ltd, Novartis Pharma K.K., AstraZeneca K.K., Bristol Myers Squibb Co, Abiomed Japan K.K., and Boehringer Ingelheim. Dr Solomon has received research grants from Aplylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetix, Eisai, Gilead, GlaxoSmithKline, Ionis, Lone Star Heart, Medoblast, MyoKardia, National Institutes of Health/National Heart, Lung and Blood Institute, Novartis, Sanofi Pasteur, and Theracos; and has consulted for Akros, Aplylam, Amgen, AstraZeneca, Bayer, BMS, Cardior, Cytoviva, Cytokinetix, Gilead, GlaxoSmithKline, Ironwood, Merck, MyoKardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardulion, AdBioIme, Jansen, Cardiac Dimensions, and Tenaya. Dr Abraham has received consulting fees from Boehringer Ingelheim, Cardionomic, Zoll Respicardia, scPharmaceuticals, Sensible Medical, and Vectorious; has received salary support from V-Wave Medical; and has served as a speaker for Edwards Lifesciences. Dr O’Connor has received grant or research support from Merck; and consulting fees from Merck, Bayer, and Abiomed. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Mitchell A. Psotka, Inova Schar Heart and Vascular, 3300 Gallows Road, Falls Church, Virginia 22042, USA. E-mail: mitchell.psotka@inova.org. @mpsotka, @HFCollaboratory.

REFERENCES


**KEY WORDS** classification, heart failure, left ventricular ejection fraction, phenotyping